T cells from HLA A2+ healthy donors were co-cultured with autologous dendritic cells (DC) loaded with apoptotic tumor cells expressing rat neu, and were induced to mature by tumor necrosis factor (TNF)α and interleukin (IL)-1β (mDCneu) or by the CCL16 chemokine (CCL16/mDCneu). Priming by CCL16/mDCneu induces a larger population of T cells that express cytoplasmatic interferon (IFN)γ, TNFα, perforin and granzyme B compared to those primed by mDCneu. T cells primed by CCL16/mDCneu release IFNγ in response to human HER-2+ cells and kill human HER-2+ target cells more efficiently than those primed by mDCneu. Our results show that both the loading of DC with xenogeneic rat neu and their maturation by CCL16 are two issues of critical importance for the elicitation of an effective response to human HER-2 in T cells from normal donors.
RobbinsPFKawakamiY. Human tumor antigens recognized by T cells. Curr Opin Immunol1996; 8:628–36.
2.
DisisMLCheeverMA. HER-2/neu protein: A target for antigen specific immunotherapy of human cancer. Adv Cancer Res1997; 71:343–71.
3.
CoussensLYang-FengTLChenY-CLE. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science1985; 230:1132–9.
4.
SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987; 235:177–82.
5.
BerchuckAKamelAWhitakerR. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res1990; 50:4087–91.
6.
BaxevanisCNSotiriadouNNGritzapisADSotiropoulouPAPerezSACacoullosNTPapamichailM. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother2006; 55(1):85–95.
7.
PupaSMTagliabueEMénardSAnichiniA. HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J Cell Physiol2005; 205(1):10–18.
8.
BrossartPWirthsSStuhlerGReichardtVLKanzLBruggerW. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood2000; 96(9):3102–8.
9.
DisisMLGooleyTARinnKDavisDPiepkornMCheeverMAKnutsonKLSchiffmanK. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol2002; 20 (11):2624–32.
10.
MurrayJLPrzepiorkaDIoannidesCG. Clinical trials of HER-2/neu-specific vaccines. Semin Oncol2000; 27(6,1):71–5.
11.
KiesslingRWeiWZHerrmannFLindencronaJAChoudhuryAKonoKSeligerB. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res2002; 85:101–44.
12.
MorganDJKreuwelHTCFleckSLevitskyHIPardollDMShermanLA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol1998; 160:643–51.
13.
MullinsDWBullockTNColellaTARobilaVVEngelhardVH. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J Immunol2001; 167(9):4853–60.
14.
PupaSMIezziMDi CarloEInvernizziACavalloFMeazzaRComesAFerriniSMusianiPMénardS. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res2005; 65(3):1071–8.
15.
GalloPDharmapuriSNuzzoMMaldiniDIezziMCavalloFMusianiPForniGMonaciP. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer2005; 113(1):67–77.
16.
JacobJRadkevichOForniGZielinskiJShimDJonesRFWeiWZ. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol2006; 240(2):96–106.
17.
GritzapisADMahairaLGPerezSACacoullosNTPapamichailMBaxevanisCN. Vaccination with human HER-2/neu (435–443) CTL peptide induces effective antitumor immunity against HER-2/neuexpressing tumor cells in vivo. Cancer Res2006; 66(10):5452–60.
18.
NagataYFurugenRHiasaA. Peptides derived from wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol1997; 159:1336–43.
19.
CappelloPCaorsiCBosticardoMDe AngelisSNovelliFForniGGiovarelliM. CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J Leuk Biol2004; 75:135–142.
20.
CappelloPFraoneTBarberisLCostaCHirschEEliaARCaorsiCMussoTNovelliFGiovarelliM. CCL16 induce a novel maturation program in human immature monocyte-derived dendritic cells. J Immunol2006; 177:6143–51.
21.
LolliniPLCavalloFNanniPForniG. Vaccines for tumour prevention. Nat Rev Cancer2006; 6(3):204–16.
22.
SilkAWFinnOJ. Cancer vaccines: A promising cancer therapy against all odds. Future Oncol2007; 3(3):299–306.
23.
KoBKKawanoKMurrayJLDisisMLEffersonCLKuererHMPeoplesGEIoannidesCG. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res2003; 9:3222–34.
24.
HeathWRCarboneFR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol2001; 19:47–64.
25.
SchnurrMScholzCRothenfusserSGalambosPDauerMRobeJEndresSEiglerA. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res2002; 62(8):2347–52.
26.
BerardFBlancoPDavoustJ. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med2000; 192:1535–44.
27.
HoffmannTKMeidenbauerNDworackiGKanayaHWhitesideTL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res2000; 60:3542–9.
28.
CappelloPTriebelFIezziM. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res2003; 63(10):2518–25.
29.
NanniPLanduzziLNicolettiG. Immunoprevention of mammary carcinoma in HER-2/neu trasgenic mice is IFN-gamma and B cell dependent. J Immunol2004; 173(4):2288–96.
30.
CavalloFOffringaRvan der BurghSHForniGMeliefCJ. Vaccination for treatment and prevention of cancer in animals models. Adv Immunol2006; 90:175–213.
